Tuesday, November 21, 2006

Enzon (ENZN)

More than 50x the normal volume of ENZN Feb10 calls have traded today. The company is in the midst of a phase 1 trial of Oncaspar to assess its safety and use in the treatment of advanced solid tumors and lymphomas in combination with Gemzar(R). These Feb10s might be worth a shot since they are only trading at around .30-cents.

No comments: